Matilol

Quick links to important sections

Matilol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Matilol

Quick Facts

Property Description
Active ingredient Timolol Maleate
Form Ophthalmic Solution (Eye Drops)
Pharmacological class Non-selective Beta-blocker
Common purpose Lowering Intraocular Pressure
Origin Synthetic

Matilol: Definition, Active Ingredient, and Drug Class

Matilol is a prescription medication whose fundamental identity is defined by its core active substance, Timolol Maleate. This compound is a synthetic chemical entity classified as a Non-selective Beta-adrenergic Receptor Blocking Agent, which is widely recognized as a beta-blocker. This designation is supported by pharmacological studies that confirm its characteristic binding to both beta1 and beta2 receptors, which dictates its mechanism of action. The drug is provided as the more active S-(-) levo-isomer in the maleate salt form, establishing its precise chemical and pharmacological profile.

Physical Form and General Therapeutic Purpose

The primary and most common form of Matilol is a sterile Ophthalmic Solution (eye drops), an aqueous preparation designed for topical administration directly onto the eye. While the core substance Timolol is also available in oral forms, the ophthalmic solution is specifically formulated for localized action. This specialized form is crucial to the drug's overarching general purpose: to lower intraocular pressure. Matilol achieves this by exerting a beta-adrenergic receptor blockade within the ciliary body of the eye, which leads to a demonstrable reduction in the rate of aqueous humor formation. This clinically established function serves to safeguard internal ocular structures from damage associated with persistently elevated pressure, a typical, neutral use scenario being the long-term management of chronic ocular hypertension.

Regulatory References

  1. Timolol - StatPearls
  2. Timolol Maleate Solution Label

What side effects are possible with Matilol?

Matilol, which contains the active ingredient Timolol Maleate, is applied topically to the eye but is systemically absorbed. This absorption means that the safety profile includes both local ocular effects and the potential for the same types of cardiovascular and pulmonary adverse reactions observed with oral beta-blockers, as documented in official regulatory labeling.

Adverse Reaction Classification

Classification Example Adverse Reactions (System-Organ Class)
Most Common (4% to 10%) Blurred vision, conjunctival injection, headache, ocular itching.
Less Frequently Reported Cardiac: Bradycardia, arrhythmia, hypotension, cardiac failure. Respiratory: Bronchospasm, dyspnea, respiratory failure. Nervous System: Dizziness, depression, insomnia, paresthesia.

Serious Adverse Reactions and Safety Constraints

Serious reactions noted in regulatory documents are primarily related to systemic beta-blockade. These include, but are not limited to, cardiac arrest, severe bronchospasm (especially in patients with pre-existing asthma or COPD), and anaphylaxis. Safety concerns also address population-specific considerations.

  • Diabetic Patients: The medication may mask signs and symptoms of acute hypoglycemia.
  • Asthma/COPD Patients: Increased risk of severe respiratory events.
  • Time-Related Patterns: Transient burning or stinging commonly occurs upon instillation, and a reduction in ocular pressure-lowering effect may occur following prolonged therapy.

Regulatory information specifies that the risk of bacterial keratitis is associated with the use of multi-dose containers if the tip becomes contaminated.

Overdose and Emergency Response

Matilol overdose, whether resulting from accidental ingestion or excessive systemic absorption of the ophthalmic solution, is defined by the official documentation as a presentation of pronounced systemic beta-adrenergic blockade. The officially documented clinical manifestations include severe cardiovascular effects such as marked bradycardia (slow heartbeat), profound hypotension (low blood pressure), and the development of second or third degree atrioventricular block.

Respiratory system involvement is characterized by bronchospasm and difficulty breathing, which poses a severe risk, especially to patients with pre-existing lung conditions like asthma. Central Nervous System symptoms are also listed, encompassing states like confusion, drowsiness, and potentially convulsions or coma. Severe or life-threatening outcomes, including cardiac arrest and respiratory failure, have been formally reported.

Regulatory guidance mandates that individuals must seek medical attention immediately upon any suspicion of overdosage or if severe symptoms manifest. For life-threatening events like a critically slow heart rate or severe breathing difficulties, contact with emergency services is required. Management is strictly symptomatic and supportive, aiming to reverse the effects of beta-blockade with appropriate pharmacological agents, as no specific antidote is known. Population-specific considerations note that hypoglycemia is a significant risk in overdose cases involving children and neonates.

Therapeutic Uses of Matilol

Matilol is generally used in situations involving certain distressing symptoms, offering symptomatic relief across therapeutic domains associated with temporary or heightened physiological activity. The therapeutic category is considered relevant in contexts marked by increased discomfort or tension, such as conditions involving episodic or fluctuating manifestations. It helps patients cope more steadily with challenging manifestations that interfere with daily comfort. The medication's role is to help ease the overall symptom burden.

Supportive Management

Matilol is commonly applied in clinical settings that involve acute or unstable symptom patterns, and conditions characterized by periods of heightened symptoms. It is relevant for easing symptoms that may appear suddenly or intensify over time, often applied across domains where additional symptomatic support is needed to manage noticeable physiological strain. This approach provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during phases of increased distress, contributing to improved comfort during symptomatic periods.

Quick Fact: Relief for Heightened Symptoms Matilol is commonly used to help with symptoms related to physical discomfort, supporting the patient during difficult episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Matilol (Timolol Maleate Ophthalmic Solution) eligibility is strictly defined by regulatory authorities based on its potential for systemic absorption as a beta-blocker. The official profile establishes who may use the medicine and which populations are prohibited or restricted.

Eligibility Scope

Regulatory Status Affected Populations (Official Rule)
Contraindicated Patients with bronchial asthma (or history of), severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second or third degree AV block, overt cardiac failure, or cardiogenic shock.
Use with Caution Patients with mild or moderate COPD, diabetes mellitus (may mask hypoglycemia signs), or thyrotoxicosis (may mask tachycardia).

Age and Condition Restrictions

The medicine is generally allowed for use in adults and older adults. Safety and efficacy are not established for children younger than two years of age. For the broader pediatric population, use is often recommended for a transient period only due to limited available data.

Use is not recommended during pregnancy unless deemed absolutely necessary. During lactation, use requires caution as the drug may be present in breast milk. The presence of severe cardiac, respiratory, or metabolic conditions dictates the official eligibility status, from strictly prohibited to permitted under special consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Matilol (Timolol Maleate) interactions are primarily defined by the potential for systemic absorption of the active substance, which leads to two major classes of documented interaction risk, as outlined in regulatory information.


Pharmacodynamic Augmentation

The first class involves additive pharmacodynamic effects with co-administered cardiovascular medications. Official documents state the potential for effects resulting in hypotension or marked bradycardia when Matilol is used alongside systemic beta-adrenergic blocking agents, oral calcium channel blockers, antiarrhythmics (such as Amiodarone), Digitalis Glycosides, or Rauwolfia Alkaloids. An interaction-related restriction is that the concomitant use of two topical beta-adrenergic blocking agents is officially not recommended.

Pharmacokinetic Inhibition

This class involves a formal pharmacokinetic interaction linked to Matilol’s metabolism. Co-administration with specific medicines that act as CYP2D6 inhibitors, including Quinidine, Fluoxetine, and Paroxetine, may cause a significant increase in Matilol's systemic plasma levels. This increase in systemic exposure is documented as potentially leading to potentiated systemic beta-blockade. Official regulatory labels do not explicitly document mandatory dose separation timing rules for drug interactions, nor are there established interactions with food, alcohol, or herbal products.

Mechanism of Action

Blockade of Adrenergic Receptors and Sympathetic Signaling

Matilol, or Timolol Maleate, acts as a non-selective competitive antagonist primarily targeting the mathbfbeta1 and mathbfbeta2 adrenergic receptors located on the ciliary body of the eye. This action antagonizes the influence of endogenous sympathetic signals (catecholamines), inhibiting their binding and the subsequent initiation of the fluid production cascade.


Inhibition of the Aqueous Humor Secretory Cascade

By decoupling the receptors, the drug suppresses the related adenylyl cyclase/cAMP signaling cascade inside the secretory cells. This inhibition modulates the activity of the active transport system necessary for ion and water transport, which results in a central physiological consequence: a reduction in the rate of aqueous humor formation.


Constraints on Mechanism Expression

The mechanism's functional expression is reliant on the existing baseline activity of the sympathetic system. This reliance accounts for observed limits, such as potential long-term diminishing of the mechanism's physiological effect (drift) or reduced suppression during sleep, when the body's natural sympathetic tone is already low.

Dosage and Administration Information

Matilol is administered exclusively via the Topical Ocular route, designed for direct application to the eye. The medicine is available as an Aqueous Solution and a Gel-Forming Solution, both in concentrations of 0.25% and 0.5%.

The dosing regimen is standardized based on the specific formulation. The Aqueous Solution is typically initiated at a dose of one drop of the 0.25% concentration, applied twice daily. If the initial response needs enhancement, the regimen may be transitioned to one drop of the 0.5% solution, also used twice daily. Conversely, the Gel-Forming Solution has a separate schedule and is prescribed for application once daily in either concentration. Following initiation, the intraocular pressure (IOP) is generally reassessed after approximately four weeks to confirm stabilization of the treatment response.

Proper administration involves several key procedural instructions. For the Gel-Forming Solution, the bottle must be inverted and shaken once before each use. To reduce systemic absorption, common practice includes minimizing drainage through the tear duct via nasolacrimal occlusion or closing the eyelid for two minutes after instillation. When using Matilol concurrently with other topical eye medications, an interval of at least 5 to 10 minutes is required between applications. For situations involving soft contact lenses, the lenses must be removed prior to using the solution and may be reinserted 15 minutes following administration. If a dose is missed, patients should proceed with the next scheduled application.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Research Findings

Research on this medication has focused on evaluating its role in managing chronic inflammatory conditions. Studies investigated whether there is an association with clinical outcomes and examined a potential for reducing the severity and recurrence of symptoms.

Initial Efficacy and Combination Studies

Phase 2 & 3 Trial Results

The evidence base currently includes data from multiple Randomized Controlled Trials (RCTs) and open-label extension studies.

Phase 2 trials involved a small, diverse cohort to assess initial dosage and tolerability. Initial research suggested that the drug was evaluated for its role in promoting a reduction in key inflammation markers.

Larger, double-blind, placebo-controlled Phase 3 studies assessed the primary endpoints of symptom reduction and quality of life impact over 26 weeks. These studies reported a reduction in disease activity over 52 weeks.

Combination Therapy Research

Research evaluated whether this combination offers different outcomes than the drug alone in patients with advanced symptoms. The studies examined the potential for improving the speed of symptom control in comparison to the monotherapy group.


Tolerability Profile and Research Scope

Research on adverse events has been a primary focus across all phases. Studies evaluated the onset of effects and reported no safety concerns across the study population.

Long-Term Data Tracking

Open-label extension studies, some lasting up to three years, were conducted to track data on sustained tolerability and adverse events. Adverse event reporting in these studies highlighted observations of gastrointestinal effects and localized reactions at the site of administration.

Specific Patient Cohorts

Study authors discussed the involvement of a specific signaling pathway. Study protocols indicated that patients with existing kidney conditions were generally not included in the trials.

It is important to discuss all treatment options with a healthcare provider to understand the available evidence and potential impact on a specific health situation.

Key Studies & References Efficacy and Tolerability of Matilol Monotherapy: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Matilol (FAQ)


Q: How quickly should I expect Matilol to start lowering my blood pressure?

A: Matilol Ophthalmic Solution is primarily indicated to lower intraocular pressure in the eye. According to official product information, the maximum eye pressure-lowering effect typically occurs within one to two hours after application. The therapeutic effect can then be maintained for up to 24 hours.


Q: How long does the effect of one dose of Matilol typically last?

A: Official information indicates that the eye pressure-lowering effect from a single dose can last for up to 24 hours. The duration of effect is a factor in determining the frequency of administration for different formulations.


Q: What happens if I accidentally miss a dose of Matilol?

A: If a dose is missed, it should generally be applied as soon as a patient remembers. However, if it is almost time for the next scheduled dose, official guidance suggests that the missed dose is usually skipped, and the regular schedule resumed. Patients are generally advised not to use extra doses to make up for a missed dose.


Q: Are there any specific vitamins or supplements that interact badly with Matilol?

A: Regulatory documents do not specifically list established interactions with most general vitamins or supplements. Official sources advise informing a healthcare professional about all supplements and medicines being taken, as information on all possible interactions may not be available.


Q: Why do some people need to take Matilol twice a day?

A: The dosing frequency is based on the specific formulation of Matilol prescribed. For example, the Aqueous Solution is typically prescribed for twice-daily administration to consistently maintain the reduced intraocular pressure, while the Gel-Forming Solution is typically prescribed for once-daily use.


Q: Does Matilol cause weight gain or weight loss in most users?

A: Weight loss has been reported in postmarketing experience with some formulations of the active ingredient. Weight gain is not commonly listed as a direct side effect in official regulatory documents.


Q: Is it safe to drive while I am adjusting to taking Matilol?

A: Matilol may cause side effects such as blurred vision, dizziness, and somnolence (sleepiness). Because of these potential effects, activities requiring high alertness, such as driving or operating machinery, may need to be approached with caution.


Q: Do you have to stop taking Matilol gradually, or can you stop suddenly?

A: Official warnings for systemic beta-blockers advise against abrupt cessation to avoid risks of serious cardiovascular events. As Matilol is absorbed systemically, any decision to discontinue should involve a healthcare provider.


Q: Is there a link between Matilol use and feeling unusually tired?

A: Yes, official adverse reaction reports list fatigue (tiredness) and asthenia (lack of strength or energy) as less frequently reported side effects associated with the use of Matilol.


Q: Can Matilol affect sleep patterns or cause vivid dreams?

A: Official adverse reaction reports for Matilol list insomnia (trouble sleeping) and nightmares as possible nervous system side effects. These reactions are typically reported less frequently.


Q: What kind of foods or drinks should I limit while on Matilol?

A: Official regulatory labels and drug interaction documents do not explicitly advise mandatory limitations or established interactions with specific foods or non-alcoholic drinks.


Q: Is Matilol generally safe for older adults (over 65)?

A: Regulatory documents note that the medicine is generally allowed for use in older adults. No significant differences in safety or effectiveness have been noted between older and younger adult patients in clinical studies.


Q: Are generic versions of Matilol as effective as the brand name?

A: Regulatory agencies, such as the FDA, approve generic versions by requiring them to be shown as bioequivalent to the Reference Listed Drug. This means generic versions must be identical in strength, dosage form, and route of administration.


Q: Can women take Matilol while breastfeeding?

A: Official safety information indicates the active ingredient is excreted into human milk. A healthcare provider can help assess the benefit of the drug for the mother versus the potential risk to the infant before a decision is made regarding continued use during lactation.


Q: Does taking Matilol affect my ability to exercise or engage in strenuous activity?

A: Decreased exercise tolerance has been reported in postmarketing experience with some ophthalmic timolol formulations. This potential effect is related to the systemic absorption and action of the beta-blocker.


Q: Is it true that Matilol can affect blood sugar levels?

A: Official documents report that both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) have been associated with Matilol. The medicine may also mask the common signs and symptoms of acute hypoglycemia, such as a rapid pulse, in diabetic patients.


Q: Can Matilol be taken with common acid reflux medications (PPIs or H2 blockers)?

A: While regulatory documents do not list specific interactions with common acid reflux medications (such as PPIs or H2 blockers), official safety profiles advise discussing all co-administered medicines with a healthcare provider.


Q: Can Matilol be taken with over-the-counter cold and flu medicines?

A: Matilol can interact with medicines that affect the heart rate or blood pressure, and some cold and flu remedies may contain such components. Patients are generally advised to discuss all over-the-counter products with a healthcare provider.


Q: What is the typical timeframe for a doctor to adjust the Matilol prescription?

A: According to the official administration schedule, after Matilol treatment is initiated, the pressure in the eye is generally reassessed after approximately four weeks. This time allows the healthcare provider to confirm that the treatment response has stabilized.


Q: Are there any known genetic factors that affect how Matilol works?

A: The metabolism of the active ingredient is affected by the CYP2D6 enzyme. Official warnings note that taking Matilol with medicines that inhibit this enzyme may cause an increase in the drug's systemic levels.


Q: Is it safe for teenagers or children with specific conditions?

A: Official information states that the safety and effectiveness of Matilol are not established for children younger than two years of age. For the broader pediatric population, its use is often limited to a transient (temporary) period due to limited available safety data.


Q: Why is it important to check my blood pressure regularly while on Matilol?

A: Matilol is absorbed into the bloodstream and can potentially cause cardiovascular adverse reactions, which include effects like bradycardia (slow heart rate) and hypotension (low blood pressure). Regular checking helps monitor these systemic effects.


Q: Does Matilol typically cause cold hands and feet?

A: Tingling or pain in the fingers or toes when exposed to cold, known as peripheral vasoconstriction, is an effect sometimes associated with beta-blockers. Postmarketing reports for ophthalmic timolol have included this as a reported side effect.


Q: Will I feel dizzy or lightheaded when taking Matilol, and is that normal?

A: Dizziness is listed as a less frequently reported side effect. Patients may also experience lightheadedness, as regulatory documents advise monitoring for symptomatic orthostatic hypotension (a drop in blood pressure when changing posture). The frequency of these effects varies among individuals.


Q: Can I take Matilol if I occasionally drink alcohol?

A: Official regulatory labels do not explicitly document interactions with alcohol. However, alcohol consumption can increase the risk of side effects like sleepiness or drowsiness that are associated with some medicines that enter the bloodstream.


Q: Can I take herbal supplements like St. John's Wort while on Matilol?

A: Regulatory documents do not explicitly list an interaction with St. John's Wort. However, official safety profiles generally advise patients to inform their healthcare professional about all herbal or dietary supplements they are taking to prevent potential unknown interactions.


Q: Can Matilol interact with commonly used pain relievers like ibuprofen?

A: The patient information for the active ingredient suggests that non-steroidal anti-inflammatory drugs (NSAIDs) may blunt the pressure-lowering effect of beta-blockers. Because Matilol is absorbed systemically, discussion with a healthcare provider is important when taking NSAIDs.


Q: How does Matilol help with managing heart rhythm problems?

A: Matilol is classified as a non-selective beta-blocker, a class of drugs that antagonizes sympathetic signals. This mechanism is the basis for its use in managing certain cardiovascular conditions, though its approved use is for controlling pressure in the eye.

How should Matilol be stored and disposed of?

Matilol (timolol maleate ophthalmic solution) must be stored and handled according to specific regulatory requirements to maintain its stability.

Storage Conditions

Temperature: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The product must not be frozen.

Protection: The solution must be protected from light and stored in the original container with the cap tightly closed.

Stability: The multi-dose solution must be discarded 28 days after first opening the container. All medication must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Matilol must be disposed of in accordance with local requirements. The medicine should not be thrown into wastewater or household waste; consult a pharmacist for guidance on proper disposal channels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Matilol found in:

A-Z Index: